Contrast-Free Magnetic Resonance Imaging for Breast Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Outpatient MRI: Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires. There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care.
Study summary
Prospective, observational cohort study looking at patients either at risk of breast cancer or have clinically suspected breast to assess the diagnostic performance of quantitative, non-contrast MRI.
Eligibility
Primary outcome measure(s)
- Determine the diagnostic performance of a non-contrast MRI in breast disease — 36 months
Mapping multi-parametric algorithms and assessing diagnostic performance compared to standard of care using area under the receiver operative curve (AUROC)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Gemini One | Oxford | United Kingdom |
More Perspectum trials in the UK
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05006196 on ClinicalTrials.gov ↗ ← All trials in the UK